WuXi XDC Cayman Inc
2268.HK
HKD71.40 0.78%
Exchange: HKSE | Sector: Healthcare | Industry: Medical Diagnostics Research
Q2 2024
Published: Jun 30, 2024

Earnings Highlights

  • Revenue of $832.60M up 64.6% year-over-year
  • EPS of $0.19 increased by 116.7% from previous year
  • Gross margin of 32.1%
  • Net income of 244.11M
  • ""No earnings call transcript was provided in the input set."" - N/A

WuXi XDC Cayman Inc (2268.HK) QQ2 2024 Results Analysis: Robust Margin Expansion and Accelerating Growth in Healthcare CRO/CMO Space

Executive Summary

WuXi XDC Cayman Inc reported a strong QQ2 2024 with notable top-line growth and an expansion of profitability metrics, underpinned by a favorable mix of services and scale advantages in its CRO/CMO business. Revenue reached 832.60 million CNY, up 64.6% year-over-year, while gross profit rose 141.1% to 267.67 million CNY and gross margin improved to 32.15%. Operating income was 192.56 million CNY (operating margin 23.13%), supported by 88.30 million CNY of other income and expenses that buffered pretax profitability to 280.86 million CNY and led to net income of 244.11 million CNY (net margin 29.32%). Earnings per share stood at 0.19 CNY, up 116.7% year-over-year. Cash flow dynamics show negative operating cash flow of 112.33 million CNY, driven largely by non-cash and working capital effects, and capital expenditure of 260.92 million CNY, resulting in negative free cash flow of 373.25 million CNY for the quarter. The balance sheet remains liquidity-rich with substantial cash balances and a low debt burden, yielding a net debt position of approximately -3.41 billion CNY and a current ratio of 4.13x. Management commentary on QQ2 2024 and the broader market context was not provided in the supplied transcript, limiting direct quotes. Nevertheless, the quarterly performance signals a resilient growth trajectory in a structurally favorable ADC/CDMO market, though near-term cash flow headwinds from capex investments warrant close monitoring.Overall, the company demonstrates strong profitability, solid balance sheet strength, and favorable industry-driven growth, but investors should watch for capex-driven cash burn, order intake visibility, and competitive dynamics in the CRO/CMO space.

Key Performance Indicators

Revenue

832.60M
QoQ: 0.00% | YoY:64.59%

Gross Profit

267.67M
32.15% margin
QoQ: 0.00% | YoY:141.09%

Operating Income

192.56M
QoQ: 0.00% | YoY:89.25%

Net Income

244.11M
QoQ: 0.00% | YoY:152.86%

EPS

0.19
QoQ: 0.00% | YoY:116.65%

Revenue Trend

Margin Analysis

Key Insights

Revenue: 832,599,500 CNY (+64.59% YoY; QoQ 0.00%) Gross Profit: 267,665,500 CNY; Gross Margin: 32.15% (YoY +141.1%; QoQ 0.00%) Operating Income: 192,556,500 CNY; Operating Margin: 23.13% (YoY +89.25%; QoQ 0.00%) Net Income: 244,114,000 CNY; Net Margin: 29.32% (YoY +152.86%; QoQ 0.00%) EPS: 0.19 CNY (YoY +116.65%; QoQ 0.00%) EBITDA: 217,622,500 CNY; EBITDA Margin: 26.14% (as reported: 0.2614) Tax Rate (pre-tax to net): 13.84% (effective tax rate) ~ 0.131 Cash Flow Metrics: Net cash from operating...

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q2 2025 1,350.43 0.28 +224.4% View
Q1 2025 1,350.43 0.28 +138.9% View
Q2 2024 832.60 0.19 +64.6% View
Q1 2024 832.60 0.19 +70.8% View